The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer
Authors
Keywords
Luminal breast cancer, Late recurrence, Prognostic factor, Survival, Topoisomerase II alpha
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1186/s12885-018-4170-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha
- (2015) Wei Hua et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes
- (2015) Christopher D. Hart et al. BREAST
- Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy
- (2015) Yousaf Ali et al. TUMOR BIOLOGY
- Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer
- (2015) Jiang-Hua Qiao et al. TUMOR BIOLOGY
- Topoisomerase 2α status in invasive breast carcinoma – comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation
- (2015) Włodzimierz T. Olszewski et al. POLISH JOURNAL OF PATHOLOGY
- Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy
- (2014) Soley Bayraktar et al. MEDICAL ONCOLOGY
- Topoisomerase IIα in chromosome instability and personalized cancer therapy
- (2014) T Chen et al. ONCOGENE
- Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
- (2014) Tommaso Susini et al. OncoTargets and Therapy
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- The molecular diversity of Luminal A breast tumors
- (2013) Giovanni Ciriello et al. BREAST CANCER RESEARCH AND TREATMENT
- The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer
- (2013) S. Chen et al. EJSO
- Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer
- (2013) Elisabetta Munzone et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Luminal breast cancer: from biology to treatment
- (2013) Michail Ignatiadis et al. Nature Reviews Clinical Oncology
- Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
- (2012) Atocha Romero et al. Clinical & Translational Oncology
- Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
- (2012) Alan S. Coates et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
- (2012) George Fountzilas et al. Journal of Translational Medicine
- Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization
- (2011) Atocha Romero et al. AMERICAN JOURNAL OF PATHOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
- (2011) F. P. O’Malley et al. BREAST CANCER RESEARCH AND TREATMENT
- Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
- (2011) M. Martin et al. BREAST CANCER RESEARCH AND TREATMENT
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
- (2011) Angelo Di Leo et al. LANCET ONCOLOGY
- Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy
- (2011) Alíz Nikolényi et al. PATHOLOGY & ONCOLOGY RESEARCH
- ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
- (2010) J. C. Brase et al. CLINICAL CANCER RESEARCH
- Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer
- (2010) Christian Schindlbeck et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
- (2008) A. Rody et al. BREAST CANCER RESEARCH AND TREATMENT
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started